SCHEMBL628803

SCHEMBL628803

COC(OC)(O[C]=O)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.40
KCNN4 O15554 4/20 0.39
MAPK1 P28482 1/20 0.37
ALDH1A1 P00352 3/20 0.34
ALOX15 P16050 1/20 0.34
CYP2B6 P20813 1/20 0.34
KMT2A Q03164 2/20 0.33
GAA P10253 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.32
CYP2C19 P33261 1/20 0.31
HIF1A Q16665 1/20 0.31
TSHR P16473 3/20 0.31
CA4 P22748 1/20 0.31
HDAC3 O15379 1/20 0.31
HDAC4 P56524 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC7 Q8WUI4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL487231 0.79 MAPK1 (0.48) CES1KCNN4MAPK1ALDH1A1ALOX15
SCHEMBL28006379 0.78 MAPK1 (0.40) CES1KCNN4MAPK1ALDH1A1ALOX15
SCHEMBL6270358 0.75 MAPK1 (0.44) CES1KCNN4MAPK1ALDH1A1ALOX15
SCHEMBL131978 0.74 MAPK1 (0.44) CES1KCNN4MAPK1ALDH1A1ALOX15
SCHEMBL135667 0.74 MAPK1 (0.56) CES1KCNN4MAPK1ALDH1A1ALOX15
SCHEMBL2027830 0.73 CA1 (0.41) MAPK1ALDH1A1KMT2AGAAKDM4E
SCHEMBL183489 0.73 KIF11 (0.40) CES1KCNN4MAPK1ALDH1A1ALOX15
SCHEMBL27290020 0.72 CES1 (0.41) CES1KCNN4MAPK1ALDH1A1ALOX15
SCHEMBL7056377 0.71 MAPK1 (0.41) CES1KCNN4MAPK1ALDH1A1ALOX15
SCHEMBL11110723 0.71 MAPK1 (0.36) CES1KCNN4MAPK1ALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107002293-B Sequencing by synthesis using pulsed readout optics 艾比斯生物科学公司 2020-12-08 CN claimed
US-20200123605-A1 SEQUENCING BY SYNTHESIS USING PULSE READ OPTICS IBIS BIOSCIENCES, INC. 2020-04-23 US claimed
EP-3194643-B1 SEQUENCING BY SYNTHESIS USING PULSE READ OPTICS IBIS BIOSCIENCES INC (US) 2020-02-19 EP claimed
US-10550428-B2 Sequencing by synthesis using pulse read optics IBIS BIOSCIENCES, INC. (US) 2020-02-04 US claimed
US-20170247755-A1 SEQUENCING BY SYNTHESIS USING PULSE READ OPTICS IBIS BIOSCIENCES, INC. 2017-08-31 US claimed
EP-3194643-A1 SEQUENCING BY SYNTHESIS USING PULSE READ OPTICS Ibis Biosciences, Inc. (US) 2017-07-26 EP claimed
WO-2016044391-A1 SEQUENCING BY SYNTHESIS USING PULSE READ OPTICS IBIS BIOSCIENCES, INC. (US) 2016-03-24 WO claimed
US-8975216-B2 Articles having localized molecules disposed thereon and methods of producing same PACIFIC BIOSCIENCES OF CALIFORNIA (US) 2015-03-10 US claimed
EP-2231670-A2 PROCESS FOR THE PREPARATION OF 2-(PRIMARY/SECONDARY AMINO)HYDROCARBYL)- CARBAMOYL-7-OXO-2,6-DIAZA-BICYCLOÝ3.2.0.¨HEPTANE-6-SULFONIC ACID DERIVATIVES Basilea Pharmaceutica AG (CH) 2010-09-29 EP claimed
JP-2009532032-A 2009-09-10 JP claimed
EP-2002019-A4 ARTICLES HAVING LOCALIZED MOLECULES DISPOSED THEREON AND METHODS OF PRODUCING SAME PACIFIC BIOSCIENCES CALIFORNIA (US) 2009-07-15 EP claimed
WO-2009071638-A2 PROCESS FOR THE PREPARATION OF 2-(PRIMARY/SECONDARY AMINO)HYDROCARBYL)- CARBAMOYL-7-OXO-2,6-DIAZA-BICYCLO[3.2.0.]HEPTANE-6-SULFONIC ACID DERIVATIVES BASILEA PHARMACEUTICA AG (CH) 2009-06-11 WO claimed
EP-2002019-A2 ARTICLES HAVING LOCALIZED MOLECULES DISPOSED THEREON AND METHODS OF PRODUCING SAME Pacific Biosciences of California, Inc. (US) 2008-12-17 EP claimed
US-20080009007-A1 CONTROLLED INITIATION OF PRIMER EXTENSION PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2008-01-10 US claimed
WO-2007123763-A2 ARTICLES HAVING LOCALIZED MOLECULES DISPOSED THEREON AND METHODS OF PRODUCING SAME PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2007-11-01 WO claimed
US-20070238679-A1 Articles having localized molecules disposed thereon and methods of producing same PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) 2007-10-11 US claimed
US-5143854-A LARGE SCALE PHOTOLITHOGRAPHIC SOLID PHASE SYNTHESIS OF POLYPEPTIDES AND RECEPTOR BINDING SCREENING THEREOF AFFYMAX TECHNOLOGIES N.V. (AN) 1992-09-01 US claimed
US-20240190894-A1 CITRATE SALT, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME FOGHORN THERAPEUTICS INC. 2024-06-13 US disclosed
EP-0292808-A2 Substituted vinyl cephalosporins, process for their preparation and their use as medicines BAYER AG (DE) 1988-11-30 EP disclosed
EP-0284954-A2 Cephalosporinderivatives, process for their preparation and their use in pharmaceutical products BAYER AG (DE) 1988-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190894-A1 CITRATE SALT, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THE SAME CS, SMARCC2, SMARCC1 CES1 629/4885KCNN4 2735/4885MAPK1 3103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.